p73γ transactivates the p21 promoter through preferential interaction with the p300/CBP-associated factor in human prostate cancer cells

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 411-416

  Momii, Yasutomo ^a   Izumi, Hiroto ^a   Shiota, Masaki ^a   Onitsuka, Takamitsu ^a   Abe, Tatsuya ^b   Kobayashi, Hidenori ^b   Miyamoto, Naoya ^a   Uchiumi, Takeshi ^a   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Acetylation; Gene expression; p300 CBP associated factor; p73

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; ISOPROTEIN; LUCIFERASE; NUCLEAR PROTEIN; OLIGONUCLEOTIDE; PCAF PROTEIN, HUMAN; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; UNCLASSIFIED DRUG;

ACETYLATION; ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOPRECIPITATION; MALE; METABOLISM; MUTATION; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; PROTEIN BINDING; TRANSACTIVATION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ALTERNATIVE SPLICING; BINDING SITES; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HISTONE ACETYLTRANSFERASES; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; MALE; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDES; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN ISOFORMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 34548537472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.411     Document Type: Article

References (29)

1. Royds JA and Iacopetta B: p53 and disease: when the guardian angel fails. Cell Death Differ 13: 1017-1026, 2006.
2. Gomez-Lazaro M, Fernandez-Gomez FJ and Jordan J: p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem 60: 287-307, 2004.
3. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005. (Pubitemid 40638098)
4. Schuler M and Green DR: Transcription, apoptosis and p53: catch-22. Trends Genet 21: 182-187, 2005. (Pubitemid 40269857)
5. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M and Prives C: High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 12: 462-472, 1998. (Pubitemid 28101009)
6. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M and Kohno K: Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15-27, 2005. (Pubitemid 40081291)
7. Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y and Kohno K: Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 276: 7534-7540, 2001.
8. Vikhanskaya F, Marchini S, Marabese M, Galliera E and Broggini M: p73α overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res 61: 935-938, 2001. (Pubitemid 32174407)
9. Kim KC, Jung CS and Choi KH: Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells. Arch Pharm Res 29: 152-158, 2006.
10. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M and Kohno K: Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224-4228, 1996. (Pubitemid 26305020)
11. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, Uchiumi T, Kuwano M and Kohno K: Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59: 342-346, 1999. (Pubitemid 29048865)
12. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K and Kohno K: p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-31702, 2002. (Pubitemid 34968973)
13. Stros M, Ozaki T, Bacikova A, Kageyama H and Nakagawara A: HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277: 7157-7164, 2002. (Pubitemid 34953105)
14. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY and Melino G: The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113: 1661-1670, 2000. (Pubitemid 30333115)
15. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M and Melino G: Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188: 1763-1768, 1998. (Pubitemid 28516121)
16. Ueda Y, Hijikata M, Takagi S, Chiba T and Shimotohno K: New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18: 4993-4998, 1999. (Pubitemid 29425306)
17. Dornan D, Shimizu H, Perkins ND and Hupp TR: DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem 278: 13431-13441, 2003. (Pubitemid 36800117)
18. Iyer NG, Ozdag H and Caldas C: p300/CBP and cancer. Oncogene 23: 4225-4231, 2004. (Pubitemid 38758588)
19. Zhao LY, Liu Y, Bertos NR, Yang XJ and Liao D: PCAF is a coactivator for p73-mediated transactivation. Oncogene 22: 8316-8329, 2003. (Pubitemid 37485524)
20. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M and Kohno K: Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19: 6194-6202, 2000. (Pubitemid 32641832)
21. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH and Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-324, 1996. (Pubitemid 26260451)
22. Torigoe T, Izumi H, Wakasugi T, Niina I, Igarashi T, Yoshida T, Shibuya I, Chijiiwa K, Matsuo K, Itoh H and Kohno K: DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1. J Biol Chem 280: 1179-1185, 2005.
23. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K and Funa K: Mechanism for the transcriptional repression by c-Myc on PDGFβ-receptor. J Cell Sci 114: 1533-1544, 2001. (Pubitemid 32427839)
24. Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Yoshida T, Itoh H and Kohno K: Binding of RNA to p53 regulates its oligomerization and DNA-binding activity. Oncogene 23: 4371-4379, 2004. (Pubitemid 38850416)
25. Izumi H, Ohta R, Nagatani G, Ise T, Nakayama Y, Nomoto M and Kohno K: p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-α-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem J: 373: 713-722, 2003. (Pubitemid 36981081)
26. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD and Berger SL: p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19: 1202-1209, 1999. (Pubitemid 29046862)
27. Takagi S, Ueda Y, Hijikata M and Shimotohno K: Overproduced p73α activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Lett 509: 47-52, 2001. (Pubitemid 33153079)
28. Liu G and Chen X: The C-terminal sterile alpha motif and the extreme C terminus regulate the transcriptional activity of the α isoform of p73. J Biol Chem 280: 20111-20119, 2005. (Pubitemid 41379541)
29. Racek T, Mise N, Li Z, Stoll A and Putzer BM: C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J Biol Chem 280: 40402-40405, 2005. (Pubitemid 41780526) Technology Technology Technology